Download PDF
Thromb Haemost 1971; 26(02): 235-250
DOI: 10.1055/s-0038-1653672
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Partial Purification and Characterization of Urinary Procoagulant

N Aoki M. D.
1   Belle Bonfils Memorial Blood Bank and Department of Medicine, University of Colorado Medical Center, 4200 East Ninth Avenue, Denver/Colorado 80220, U.S.A
,
K. N von Kaulla M. D.
1   Belle Bonfils Memorial Blood Bank and Department of Medicine, University of Colorado Medical Center, 4200 East Ninth Avenue, Denver/Colorado 80220, U.S.A
› Author AffiliationsSupported by a grant from the Belle Bonfils Memorial Blood Bank, Denver/Colorado.
Further Information

Publication History

Publication Date:
28 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

Partial purification of the human urinary procoagulant was achieved and some of its properties characterized. Purification was accomplished by adsorption of urine with BaSO4, citrate elution, isoelectric precipitation followed by (NH4)2SO4 precipitation and chromatography on hydroxylapatite and Sephadex G-200. Sucrose gradient ultracentrifugation yielded two active components with different sedimentation rates. On electrophoresis the heavier component did not enter the polyacrylamide gel, and the smaller one gave no precipitin band with antihuman serum on immunodiffusion, indicating that the procoagulant does not originate from blood. The purified procoagulant required phospholipids or platelets to activate prothrombin in the presence of coagulation factors V, VII, X and Ca++, while the crude procoagulant preparations activated prothrombin to some extent without an addition of phospholipids or platelets. Thus, the purified urinary procoagulant does not act as a typical tissue thromboplastin whereas the crude preparation may contain it as a component or contaminant. Phosphorus-containing material which may be part of a moiety endowing crude procoagulant with tissue thromboplastin-like activity is largely removed by the purification procedure resulting in low levels in the purified procoagulant.

The possible identity (relationship ? ) of urinary procoagulant with the protein component of tissue thromboplastin is discussed.

 

  • References

  • 1 Aoki N, von Kaulla K. N. The procoagulant in human urine: Purification, assay and some biochemical and physiological properties. Thrombos. Diathes. haemorrh. (Stuttg) 16: 586 1966;
    PubMedGoogle Scholar
  • 2 Aoki N, von Kaulla K. N. â1C-globulin and synthetic fibrinolytic agents. Proc. Soc. Exp. Biol. (N. Y) 130: 101 1969;
    CrossrefPubMedGoogle Scholar
  • 3 Astrup T, Muellertz S. Fibrin plate method for estimating fibrinolytic activity. Arch. Biochem 40: 346 1952;
    CrossrefPubMedGoogle Scholar
  • 4 Barthels M, Seegers W. H. Substitution of lipids with bile salts in the formation of thrombin. Thrombos. Diathes. haemorrh. (Stuttg) 22: 13 1969;
    PubMedGoogle Scholar
  • 5 Bell W. N, Alton H. G. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature (Lond) 174: 880 1954;
    CrossrefPubMedGoogle Scholar
  • 6 Biggs R, Macfarlane R. G. Human Blood Coagulation and Its Disorders. 390 Blackwell, Oxford: 1957
    Google Scholar
  • 7 Brecher G, Cronkite E. P. Morphology and enumeration of human blood platelets. J. appl. Physiol 03: 365 1950;
    CrossrefPubMedGoogle Scholar
  • 8 Caldwell J, von Kaulla K. N, von Kaulla E, Seegers W. H. Procoagulant material from human urine in prothrombin activation. Thrombos. Diathes. haemorrh. (Stuttg) 09: 53 1963;
    PubMedGoogle Scholar
  • 9 Davis B. J. Disc electrophoresis. II. Method and application to human serum proteins. Ann. N. Y. Acad. Sci 121: 404 1964;
    PubMedGoogle Scholar
  • 10 Deutsch E, Irsigler K, Lomoshitz H. Studien über Gewebethromboplastin. 1. Reinigung, chemische Charakterisierung und Trennung in einen Eiweiß- und Lipoidanteil. Thrombos. Diathes. haemorrh. (Stuttg) 12: 12 1964;
    PubMedGoogle Scholar
  • 11 Esnouf M. P, Macfarlane R. G. Enzymology and the blood clotting mechanism. Advanc. Enzymology 30: 255 1968;
    PubMedGoogle Scholar
  • 12 Ferguson J. H. Thromboplastic enzymes. Fed. Proc 23: 762 1964;
    PubMedGoogle Scholar
  • 13 Fiske C. H, Subbarow Y. The colorimetric determination of phosphorus. J. biol. Chem 66: 375 1925;
    PubMedGoogle Scholar
  • 14 Grunke W. Studien über die Blutgerinnung mit besonderer Berücksichtigung der Haemophi- lie. I. Mitteilung: Einfluß des Harnes auf die Gerinnung haemophilen Blutes. Z. ges. exp. Med 96: 512 1935;
    CrossrefPubMedGoogle Scholar
  • 15 Haslam R. J. Role of adenosine diphosphate in the aggregation of human blood platelets by thrombin and fatty acids. Nature (Lond) 202: 765 1964;
    CrossrefPubMedGoogle Scholar
  • 16 Hecht E. R. Chemical nature of human brain thromboplastin. Nature (Lond) 214: 197 1967;
    CrossrefPubMedGoogle Scholar
  • 17 Hecht E. R, Cho M. H, Seegers W. H. Thromboplastin: Nomenclature and preparation of protein-free material different from platelet factor 3 or lipid activator. Amer. J. Physiol 193: 584 1958;
    PubMedGoogle Scholar
  • 18 Hecht E. R, van Lit W. LOosterbaan. Über die chemische Natur des Thromboplastins aus menschlicher Hirnsubstanz. Thrombos. Diathes. haemorrh. (Stuttg) 18: 223 1967;
    PubMedGoogle Scholar
  • 19 Hecht E. R, Wijngaards G. Recent investigations on the chemical nature of thromboplastin (“TP”) from human brain. Thrombos. Diathes. haemorrh. (Stuttg) 21: 534 1969;
    PubMedGoogle Scholar
  • 20 Ishizaka K, Ishizaka T, Lee E. H, Fudenberg H. Immunochemical properties of human γA isohemagglutinin. I. Comparison with γG- and γM-globulin antibodies. J. Immunol 95: 197 1965;
    PubMedGoogle Scholar
  • 21 Johnson A, Woernley D, Pressman D. Sedimentation properties of human and sheep erythrocyte hemolysins. J. Immunol 79: 234 1957;
    PubMedGoogle Scholar
  • 22 Joist H, Alkjaersig N. Uroplastin, its nature and its excretion pattern in health and in certain disease states. Thrombos. Diathes. haemorrh. (Stuttg) 18: 425 1967;
    PubMedGoogle Scholar
  • 23 Lowry O. H, Rosebrough N. J, Farr A. L, Randall R. J. Protein measurement with Folin phenol reagent. J. biol. Chem 193: 265 1951;
    PubMedGoogle Scholar
  • 24 Martin R. G, Ames B. N. A method for determining the sedimentation behavior of enzymes: Application to protein mixtures. J. biol. Chem 236: 1372 1961;
    PubMedGoogle Scholar
  • 25 Matsumura T, Hutt M. P, von Kaulla K. N. Urinary procoagulant excretion in experimental renal disease. Proc. Soc. exp. Biol. (N. Y) 127: 147 1968;
    CrossrefPubMedGoogle Scholar
  • 26 Matsumura T, Hutt M. P, von Kaulla K. N. Urinary procoagulant excretion and its relation to kidney function. Nephron 07: 165 1970;
    CrossrefPubMedGoogle Scholar
  • 27 Matsumura T, von Kaulla K. N. Procoagulant content of human urine in health and disease. Amer. J. clin. Path 50: 198 1968;
    PubMedGoogle Scholar
  • 28 Nemerson Y. The phospholipid requirement of tissue factor in blood coagulation. J. clin. Invest 47: 72 1968;
    CrossrefPubMedGoogle Scholar
  • 29 Nemerson Y. Characteristics and lipid requirements of coagulant protein extracted from Inna: and brain: The specificity of the protein compound of tissue factor. J. clin. Invest 48: 322 1969;
    CrossrefPubMedGoogle Scholar
  • 30 Nemerson Y, Pitlick F. A. Purification and characterization of the protein component of tissue factor. Biochemistry 09: 5100 1970;
    CrossrefPubMedGoogle Scholar
  • 31 Nemerson Y, Spaet T. H. The activation of Factor X by extracts of rabbit brain. Blood 23: 657 1964;
    PubMedGoogle Scholar
  • 32 Petermann M. L. The Physiological and Chemical Properties of Ribosomes. 38 Elsevier, Amsterdam: 1964
    Google Scholar
  • 33 Ploug J, Kjeldgaard N. O. Urokinase. An activator of plasminogen from human urine. I. Isolation and properties. Biochim. biophys. Acta (Amst) 24: 278 1957;
    CrossrefPubMedGoogle Scholar
  • 34 Seegers W. H. The purification of prothrombin. Rec. Chem. Progr 13: 143 1952;
    PubMedGoogle Scholar
  • 35 Seegers W. H. Blood clotting mechanisms: Three basic reactions. Ann. Rev. Physiol 31: 269 1969;
    CrossrefPubMedGoogle Scholar
  • 36 Seegers W. H, Smith H. P. Factors which influence the activity of purified thrombin. Amer. J. Physiol 137: 348 1942;
    PubMedGoogle Scholar
  • 37 Tissières A, Watson J. D, Schlessinger D, Hollingsworth B. R. Ribonucleoprotein particles from Escherichia coli. J. Mol. Biol 01: 221 1959;
    CrossrefPubMedGoogle Scholar
  • 38 Tocantins L. M, Lindquist J. N. Thromboplastic activity of the urine. Proc. Soc. exp. Biol. (N. Y) 65: 44 1947;
    CrossrefPubMedGoogle Scholar
  • 39 von Kaulla K. N. Methods for preparation of purified human thromboplastin and fibrinolysokinase from urine. Acta haemat. (Basel) 16: 315 1956;
    CrossrefPubMedGoogle Scholar
  • 40 Wallach D. F. H, Maurice P. A, Steele B. B, Surgenor D. M. Studies on the relationship between the colloidal state and clot-promoting activity of pure phosphatidylethanolamines. J. biol. Chem 234: 2829 1959;
    PubMedGoogle Scholar
  • 41 Ware A. G, Seegers W. H. Serum Ac-globulin: Formation from plasma Ac-globulin, role in blood coagulation, partial purification, properties, and quantitative determination. Amer. J. Physiol 152: 567 1948;
    PubMedGoogle Scholar
  • 42 Ware A. G, Seegers W. H. Two-stage procedure for the quantitative determination of prothrombin concentrations. Amer. J. clin. Path 19: 471 1949;
    PubMedGoogle Scholar
  • 43 Williams W. J. The activity of human placenta microsomes and brain particles in blood coagulation. J. biol. Chem 241: 1840 1960;
    PubMedGoogle Scholar